SAN DIEGO – Third quarter Fiscal Year 2025 results for Medtrade exhibitor Resmed revealed an 8% revenue increase (to $1.3 billion) compared to the prior year period. Additional highlights include:
• an income from operations increase of 14%; non-GAAP income from operations up 13%;
• operating cash flow of $579 million; and
• diluted earnings per share of $2.48 with non-GAAP diluted earnings per share of $2.37.

“Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for our best-in-class products and software solutions,” said Resmed’s Chairman and CEO, Mick Farrell. “We delivered 9% constant currency revenue growth and 140 bps improvement in non-GAAP gross margin. These results are evidence that sleep health customers recognize our products and software solutions as the gold standard for care.

“Our continued growth was achieved by the incredible commitment of our team that has created a clear market-leading value proposition in connected digital health,” Farrell continued. “We remain laser-focused on continuing to address the over 2.3 billion people around the globe with sleep health and breathing health issues and all those who need world-class software for healthcare delivered at home. We will continue to drive increased patient flow as we accelerate education and awareness outreach to physicians, providers, patients, and beyond, ensuring a strong pipeline of people who need access to our products and solutions to improve their lives.”